Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

J&J’s IL-23 inhibitor Tremfya (guselkumab), meanwhile, has also been filed for UC and Crohn’s, with a decision due in the coming months, although, AstraZeneca shelved its own drug in the class ...

Effective from 1 April 2025, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S and Totalkredit A/S will be adjusted. The new coupon rates will apply from 1 April 2025 to 30 ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...